Synthesis of trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid and its radiolabelling with 99mTc for the detection of skeletal metastases

Nuclear Medicine Communications

Volumn 27, Issue 8, 2006, Pages 619-626

  Panwar, Puja ^a,b   Chuttani, Krishna ^a   Mishra, Pushpa ^a,c   Sharma, Rajnish ^a   Mondal, Anupam ^a   Kumar Mishra, Anil ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b Divisions of Cyclotron and Radiopharmaceutical Sciences   (United States)

^c Department of Nuclear Medicine ^*  (United States)

Author keywords

Bone imaging; CDTMP

Indexed keywords

1,2 CYCLOHEXYLDINITRILOTETRAMETHYLENE PHOSPHONIC ACID TECHNETIUM TC 99M; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ARTICLE; BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; CANCER CYTODIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; FEMALE; FOLLOW UP; HUMAN; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; RABBIT; SOFT TISSUE; STRUCTURE ANALYSIS;

ANIMALS; BONE NEOPLASMS; HUMANS; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; PHOSPHONIC ACIDS; RABBITS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 33748111118     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200608000-00004     Document Type: Article

References (20)

1. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 2001; 31:62-68.
2. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003; 97(suppl):859-865.
3. 99mTc-HDP for the detection of bone metastases. Eur J Nucl Med 1983; 8:118-122.
4. 99mTc-MDP agents. Eur J Nucl Med 1983; 8:395-397.
5. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone targeted therapy for hormone refractory prostate carcinoma: randomized phase II trials with the new high-energy radiopharmaceutical rhenium-188 hydroxythylidinediphosphonate. J Clin Oncol 2003; 21:2869-2875.
6. Franzius C, Schuck A, Bielack SS. High-dose samarium-153 ethylenediaminetetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20:1953-1954.
7. Van Rensburg AJ, Alberts AS, Louw WK. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153 EDTMP. J Nucl Med 1998; 39:2110-2115.
8. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35:63-69.
9. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jakobsson M, et al. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994; 38(4, suppl 1):123-127.
10. Moedritzer K, Irani R. The direct synthesis of α-aminomethylene phosphonic acids: Mannich type reaction with orthophosphorous acid. J Org Chem 1966; 31:1603.
11. Bailya T, Burgada R, Lecouvey M, Neuman A, Prangé T. Racemic trans-1,2-diaminocyclohexane as a template in the synthesis of ligands for transition metal and actinide in vivo detoxification. Phosphorous, Sulfur, Silicon 1995; 101:131-140.
12. Bisaz S, Jung A, Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 1978; 54:265-272.
13. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11:269-280.
14. Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41:289-318.
15. Francis MD, Ferguson DL, Tofe AJ, Bevan JA, Michaels SE. Comparative evaluation of three diphosphonates in vitro adsorption (C-14 labeled) and in vivo osteogenic uptake (Tc-99m complexed). J Nucl Med 1980; 21:1185-1189.
16. Richards AG. Metastatic calcification detected through scanning with Tc-99m polyphosphate. J Nucl Med 1974; 15:1057-1060.
17. Val J, Lewington BM. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46(suppl):38S-47S.
18. Nair N. Relative efficacy of P-23 and Sr-89 in palliation in skeletal metastases. J Nucl Med 1999; 40:256-261.
19. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med 1992; 33:1316-1323.
20. Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, et al. Strontium-89 therapy for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64:816-822.